These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17342116)

  • 1. Vaccine leads to memory loss.
    Haanen JB; Schumacher TN
    Nat Med; 2007 Mar; 13(3):248-50. PubMed ID: 17342116
    [No Abstract]   [Full Text] [Related]  

  • 2. TLR4 agonists as vaccine adjuvants: a chemist's perspective.
    Johnson DA
    Expert Rev Vaccines; 2013 Jul; 12(7):711-3. PubMed ID: 23885814
    [No Abstract]   [Full Text] [Related]  

  • 3. Costimulatory molecules in vaccine design.
    Hodge JW; Schlom J
    Ernst Schering Res Found Workshop; 2000; (30):23-52. PubMed ID: 10943315
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccine adjuvants: is the pipeline clogged?
    Leitner WW
    Immunotherapy; 2012 Jun; 4(6):565-7. PubMed ID: 22788122
    [No Abstract]   [Full Text] [Related]  

  • 5. CDX-1401 combined with TLR agonist: positive phase 1 results.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1742. PubMed ID: 23980263
    [No Abstract]   [Full Text] [Related]  

  • 6. CD40 antibody as an adjuvant induces enhanced T cell responses.
    Carlring J; Barr TA; McCormick AL; Heath AW
    Vaccine; 2004 Sep; 22(25-26):3323-8. PubMed ID: 15308355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates.
    Morera Y; Bequet-Romero M; Ayala M; Pérez PP; Castro J; Sánchez J; Alba JS; Ancízar J; Cosme K; Gavilondo JV
    Vaccine; 2012 Jan; 30(2):368-77. PubMed ID: 22075086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients.
    Karbach J; Neumann A; Atmaca A; Wahle C; Brand K; von Boehmer L; Knuth A; Bender A; Ritter G; Old LJ; Jäger E
    Clin Cancer Res; 2011 Feb; 17(4):861-70. PubMed ID: 21163871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining a peptide vaccine with high-dose interleukin-2.
    Chapman PB
    J Clin Oncol; 2008 May; 26(14):2250-1. PubMed ID: 18467715
    [No Abstract]   [Full Text] [Related]  

  • 11. Amplification of T cell-mediated immune responses by antibody-cytokine fusion proteins.
    Lode HN; Xiang R; Gillies SD; Reisfeld RA
    Immunol Invest; 2000 May; 29(2):117-20. PubMed ID: 10854178
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunology. The adjuvant effects of antibodies.
    Smyth MJ; Kershaw MH
    Science; 2011 Aug; 333(6045):944-5. PubMed ID: 21852479
    [No Abstract]   [Full Text] [Related]  

  • 13. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
    Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
    Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
    Schlom J; Palena C; Greiner JW; Tsang KY; Grosenbach DW; Sabzevari H; Gulley JL; Arlen PM; Kass E; Hodge JW
    Dev Biol (Basel); 2004; 116():27-47. PubMed ID: 15603182
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvanticity of anti-cD40 in vaccine development.
    Cairing J; Barr T; Heath AW
    Curr Opin Mol Ther; 2005 Feb; 7(1):73-7. PubMed ID: 15732532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
    Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
    Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens.
    Barr TA; Carlring J; Heath AW
    Vaccine; 2005 May; 23(26):3477-82. PubMed ID: 15837371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses.
    Romeu B; Lastre M; Reyes L; González E; Borrero Y; Lescaille D; Pérez R; Nuñez D; Pérez O
    Vaccine; 2014 Dec; 32(51):6971-6978. PubMed ID: 25454865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?
    Romeu B; Gonzalez E; Lastre M; Pérez O
    J Drug Target; 2012 Jul; 20(6):502-8. PubMed ID: 22632258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.